Multimodality Treatment of Pancreatic Duct Carcinoma: A Prospective Randomized Study

  • N. J. Lygidakis
  • K. Stringaris
Conference paper


The poor prognosis for pancreatic duct carcinoma requires researchers to continue searching for a therapy or therapies that can provide some hope for patients. Traditional systemic chemotherapy has been proven ineffective, mainly because to deliver sufficient drug concentration to the site of the disease risks severe, toxic side effects. Systemic immunotherapy also suffers the same handicap. Surgery alone may successfully remove a tumor, but the rate of recurrence is very high. One exciting new technique is the use of a targeting method to deliver anticancer drugs directly to the affected organ. Immunochemotherapeutic drugs are suspended in an emulsion which is then injected into the splenic artery and superior mesenteric artery via two arterial catheters. The drugs are delivered directly to the organ space occupied by the tumor, and the nature of the emulsion ensures that the drugs are retained in the region for extended periods. The results of this therapy are detailed in this chapter.


Superior Mesenteric Artery Splenic Artery Pancreatic Resection Arterial Catheter Serum Glutamic Oxaloacetic Transaminase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lygidakis NJ, Ziras N, Kyparidou E, Parissis J, et al (1995) Combined immuno-pharmaceutical therapy of patients with unresectable pancreatic carcinoma. Hepato-Gastroenterology 42:1039–1052PubMedGoogle Scholar
  2. 2.
    Lygidakis NJ (1995) New frontiers in oncology. Hepato-Gastroenterology 42:432–437PubMedGoogle Scholar
  3. 3.
    Lygidakis NJ, et al (1995) Resection versus resection combined with adjuvant pre-and post-operative chemotherapy immunotherapy for metastatic colorectal liver cancer. A new look to an old problem. Hepato-Gastroenterology 42:155–161PubMedGoogle Scholar
  4. 4.
    Johnson R (1995) Pancreatic cancer. Hepato-Gastroenterology 42:294–297PubMedGoogle Scholar
  5. 5.
    Lygidakis NJ, et al (1996) Locoregional chemotherapy versus locoregional combined immunochemotherapy for patients with advanced metastatic liver disease of colorectal origin. A prospective randomized study. Hepato-Gastroenterology 43:212–220PubMedGoogle Scholar
  6. 6.
    Lygidakis NJ, et al (1995) Pancreatic head carcinoma: is pancreatic resection indicated for patients with stage III pancreatic duct cancer? Hepato-Gastroenterology 42:587–596PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1997

Authors and Affiliations

  • N. J. Lygidakis
    • 1
    • 2
  • K. Stringaris
    • 1
    • 2
  1. 1.Department of SurgeryAtheneon HospitalAthensGreece
  2. 2.Department of RadiologyAthens General HospitalAthensGreece

Personalised recommendations